Tickling the TLR7 to cure viral hepatitis

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Funk, Emily ^a   Kottilil, Shyam ^b   Gilliam, Bruce ^c   Talwani, Rohit ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis B; Hepatitis C; Hepatitis treatment; TLR7; Toll like receptors

Indexed keywords

ANA 773; ENTECAVIR; GS 9620; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON REGULATORY FACTOR 7; INTERFERON STIMULATED GENE FACTOR 3; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 12; INTERLEUKIN 6; ISATORIBINE; MYELOID DIFFERENTIATION FACTOR 88; PF 4878691; RESIQUIMOD; TENOFOVIR; TOLL LIKE RECEPTOR 7; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; TLR7 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CHRONIC DISEASE; CYTOKINE PRODUCTION; DIMERIZATION; DRUG TOLERABILITY; EFFECTOR CELL; FEVER; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTOPENIA; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; REVIEW; SEROCONVERSION; SHIVERING; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS; VIRUS REPLICATION; DRUG EFFECTS;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS C; HUMANS; TOLL-LIKE RECEPTOR 7;

EID: 84901611879     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-129     Document Type: Review

References (76)

1. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295. 10.1126/science.1183021, 3645875, 20075244.
2. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511. 10.1038/nri1391, 15229469.
3. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216. 10.1146/annurev.immunol.20.083001.084359, 11861602.
4. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145. 10.1038/35100529, 11905821.
5. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787. 10.1038/35021228, 10963608.
6. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007, 46:1769-1778. 10.1002/hep.21897, 17929296.
7. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5:215-229. 10.1038/nri1573, 15738952.
8. Talwani R, Gilliam BL, Rizza SA, Nehra V, Temesgen Z. Current status of treatment for chronic hepatitis C virus infection. Drugs Today (Barc) 2012, 48:219-231.
9. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002, 136:288-292. 10.7326/0003-4819-136-4-200202190-00008, 11848726.
10. Robek MD, Wieland SF, Chisari FV. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 2002, 76:3570-3574. 10.1128/JVI.76.7.3570-3574.2002, 136040, 11884582.
11. Janeway CA, Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 1998, 10:349-350. 10.1006/smim.1998.0142, 9799708.
12. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995. 10.1038/ni1112, 15454922.
13. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801. 10.1016/j.cell.2006.02.015, 16497588.
14. Sioud M. Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med 2006, 12:167-176. 10.1016/j.molmed.2006.02.004, 16530484.
15. West AP, Koblansky AA, Ghosh S. Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol 2006, 22:409-437. 10.1146/annurev.cellbio.21.122303.115827, 16822173.
16. Prinz M, Heikenwalder M, Schwarz P, Takeda K, Akira S, Aguzzi A. Prion pathogenesis in the absence of Toll-like receptor signalling. EMBO Rep 2003, 4:195-199. 10.1038/sj.embor.embor731, 1315829, 12612611.
17. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738. 10.1038/35099560, 11607032.
18. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006, 130:1886-1900. 10.1053/j.gastro.2006.01.038, 16697751.
19. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303:1529-1531. 10.1126/science.1093616, 14976261.
20. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004, 101:5598-5603. 10.1073/pnas.0400937101, 397437, 15034168.
21. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745. 10.1038/35047123, 11130078.
22. Baccarella A, Fontana MF, Chen EC, Kim CC. Toll-like receptor 7 mediates early innate immune responses to malaria. Infect Immun 2013, 81:4431-4442. 10.1128/IAI.00923-13, 24042114.
23. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S, Borozan I, Xie G, Selzner N, Heathcote EJ, Siminovitch K. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012, 142:1122-1131. e1121, 10.1053/j.gastro.2012.01.028, 22285807.
24. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 2007, 76:447-480. 10.1146/annurev.biochem.76.060605.122847, 17328678.
25. Gay NJ, Gangloff M. Structure and function of Toll receptors and their ligands. Annu Rev Biochem 2007, 76:141-165. 10.1146/annurev.biochem.76.060305.151318, 17362201.
26. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998, 392:245-252. 10.1038/32588, 9521319.
27. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001, 2:947-950. 10.1038/ni712, 11547333.
28. Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, Ito D, Azuma M. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1995, 154:97-105.
29. Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, Vicari A, Trinchieri G. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med 2005, 201:1157-1167. 10.1084/jem.20041930, 2213121, 15795237.
30. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008, 48:322-335. 10.1002/hep.22306, 18506843.
31. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680. 10.1038/90609, 11477402.
32. Shu SA, Lian ZX, Chuang YH, Yang GX, Moritoki Y, Comstock SS, Zhong RQ, Ansari AA, Liu YJ, Gershwin ME. The role of CD11c(+) hepatic dendritic cells in the induction of innate immune responses. Clin Exp Immunol 2007, 149:335-343. 10.1111/j.1365-2249.2007.03419.x, 1941951, 17521321.
33. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146. 10.1038/nri1001, 12563297.
34. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376. 10.1146/annurev.immunol.21.120601.141126, 12524386.
35. Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 2001, 166:5688-5694. 10.4049/jimmunol.166.9.5688, 11313410.
36. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, Ozaki Y, Tomizawa H, Akira S, Fukuhara S. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002, 195:1507-1512. 10.1084/jem.20020207, 2193542, 12045249.
37. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714. 10.7326/0003-4819-144-10-200605160-00004, 16702586.
38. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. 10.1002/hep.22759, 19330875.
39. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992, 327:1899-1905. 10.1056/NEJM199212313272702, 1280771.
40. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007, 42:513-521. 10.1007/s00535-007-2064-6, 17653645.
41. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000, 31:1014-1018. 10.1053/he.2000.5762, 10733560.
42. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011, 17:107-115. 10.1111/j.1469-0691.2010.03432.x, 21091831.
43. Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009, 137:1680-1686. 10.1053/j.gastro.2009.07.047, 2910398, 19632234.
44. American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) Recommendations for Testing, Managing and Treating Hepatitis C. http://www.hcvguidelines.org Accessed April 21, 2014.
45. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchinson JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887. 10.1056/NEJMoa1214853, 23607594.
46. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009, 119:1745-1754. 10.1172/JCI39133, 2701885, 19587449.
47. Narita M, Watanabe N, Yamahira A, Hashimoto S, Tochiki N, Saitoh A, Kaji M, Nakamura T, Furukawa T, Toba K, Fuse I, Aizawa Y, Takahashi M. A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naive T cells. Leuk Res 2009, 33:1224-1232. 10.1016/j.leukres.2009.03.047, 19443030.
48. Zhang S, Kodys K, Babcock GJ, Szabo G. CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of hepatitis C virus-infected cells and induction of interferon-alpha. Hepatology 2013, 58:940-949. 10.1002/hep.25827, 22577054.
49. Meissner EGOA, Polis MA, Kottilil S. Intrahepatic Changes in the Endogenous Interferon Response are Associated with SVR in Chronic Hepatitis C, Genotype-1 Subjects Treated with Sofosbuvir and Ribavirin 2013, Washington, D.C.: In American Association for the Study of Liver Diseases.
50. Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, Steffy KR, Bauman LA, Kerr BM, Averett DR. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005, 42:724-731. 10.1002/hep.20839, 16116638.
51. Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, Meng TC. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 2007, 47:174-182. 10.1016/j.jhep.2007.02.025, 17532523.
52. Meyer T, Surber C, French LE, Stockfleth E. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Investig Drugs 2013, 22:149-159. 10.1517/13543784.2013.749236, 23205468.
53. Harrison LI, Astry C, Kumar S, Yunis C. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol 2007, 47:962-969. 10.1177/0091270007303766, 17660481.
54. Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, Corey TP, Colman P, Kumar V, Cheng JB, Wright K, Srinivasan S, Rana K, Craig C, Horscroft N, Perros M, Westby IM, Webster R, van der Ryst E. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther 2011, 89:821-829. 10.1038/clpt.2011.60, 21451504.
55. Bergmann JF, de Bruijne J, Hotho DM, de Knegt RJ, Boonstra A, Weegink CJ, van Vliet AA, van de Wetering J, Fletcher SP, Bauman LA, Rahimy M, Appleman JR, Freddo JL, Janssen HL, Reesink HW. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther 2011, 34:443-453. 10.1111/j.1365-2036.2011.04745.x, 21707679.
56. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54:1-31.
57. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107. 10.1046/j.1365-2893.2003.00487.x, 14996343.
58. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999, 89:14-18. 10.2105/AJPH.89.1.14, 1508496, 9987458.
59. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma Cancer 1988, 61:1942-1956.
60. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005, 9:191-211. v, 10.1016/j.cld.2004.12.009, 15831268.
61. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662. 10.1002/hep.23190, 19714720.
62. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006, 44:703-712. 10.1002/hep.21290, 16941700.
63. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004, 101:6669-6674. 10.1073/pnas.0401771101, 404103, 15100412.
64. Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, Clementi M, Colombo M. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997, 26:1621-1625. 10.1002/hep.510260634, 9398007.
65. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005, 79:7269-7272. 10.1128/JVI.79.11.7269-7272.2005, 1112123, 15890966.
66. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000, 74:4165-4173. 10.1128/JVI.74.9.4165-4173.2000, 111931, 10756029.
67. Zhang X, Kraft A, Broering R, Schlaak JF, Dittmer U, Lu M. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opin Drug Discov 2012, 7:597-611. 10.1517/17460441.2012.689281, 22607384.
68. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, Rodgers S, Kurtovic J, Chang J, Lewin S, Desmond P, Locarnini S. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007, 45:102-110. 10.1002/hep.21482, 17187404.
69. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 2011, 55:762-769. 10.1016/j.jhep.2010.12.042, 21334391.
70. Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, Zhang Q, Wang J, Zhang Z, Shen F, Yuan Z. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008, 128:400-408. 10.1016/j.clim.2008.04.006, 18565796.
71. Wang H, Ryu WS. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 2010, 6:e1000986. 10.1371/journal.ppat.1000986, 2904777, 20657822.
72. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 2010, 91:2080-2090. 10.1099/vir.0.020552-0, 20375222.
73. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009, 49:1132-1140. 10.1002/hep.22751, 19140219.
74. Gane EJSE, Gordon SC, Gruener D. Safety and Pharmacodynamics of Oral TLR-7 agonist GS-9620 in patients with Chronic Hepatitis B 2013, Washington DC: American Association for the Study of Liver Disease.
75. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, Fosdick A, Frey CR, Zheng J, Wolfgang G, Halcomb RL, Tumas DB. GS-9620, an oral agonist of Toll-like receptor-7 induces prolonged suppression of Hepatitis B Virus in chronically infected chimpanzees. Gastroenterology 2013, 144:1508-1517. 10.1053/j.gastro.2013.02.003, 23415804.
76. Lopatin U, Wolfgang G, Tumas D, Frey CR, Ohmstede C, Hesselgesser J, Kearney B, Moorehead L, Subramanian GM, McHutchison JG. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. Antivir Ther 2013, 18:409-418. 10.3851/IMP2548, 23416308.